Film-style poster for the Programs for Biotech Startups presentation

Programs for Biotech Startups Programs for Biotech Startups

How to design a program and its mentoring for biotech startups.

What this presentation covers

What this presentation covers

What this presentation covers

What this presentation covers

The odds of approval

Most drug programs never reach patients

Only 13.8% of drug programs went from Phase 1 to approval; in oncology, 3.4%.

13.8% of programs go from Phase 1 to approval Wong, Siah & Lo, 2019
3.4% in oncology Wong, Siah & Lo, 2019

Success by phase

Each phase drops a third or more

Two in three programs clear Phase 1; under six in ten clear Phases 2 and 3.

  • Phase 1 to 2 66.4%66.4%
  • Phase 2 to 3 58.3%58.3%
  • Phase 3 to approval 59.0%59.0%
Probability of success by phase, 2000 to 2015 · Wong, Siah & Lo, 2019

Years in the clinic

Clinical trials take years

Median trial length rises from 1.6 years in Phase 1 to 3.8 in Phase 3.

  • Phase 1 1.6 years1.6 years
  • Phase 2 2.9 years2.9 years
  • Phase 3 3.8 years3.8 years
Median trial duration · Wong, Siah & Lo, 2019

Capital needs

Drug development needs patient capital

Counting failures and the cost of capital, one approved drug cost $2,558 million.

  • Out of pocket $1,395M$1,395M
  • With cost of capital $2,558M$2,558M
  • Plus post-approval R&D $2,870M$2,870M
R&D cost per approved drug, 2013 dollars · DiMasi, Grabowski & Hansen, 2016

Biomarkers and success

Biomarker selection improves the odds

Trials that used biomarkers to select patients had higher overall success rates.

  • With biomarker selection almost twice the success
  • Without the lower baseline

Lab access

Give founders bench space, not just desks

Wet labs and core equipment cost too much for one seed-stage team, so share them.

  • Shared wet lab benches by the month
  • Core equipment sequencing, imaging, cell culture
  • Biosafety support permits and training
  • Contract research vetted partners

IP and tech transfer

Settle the license before the round

US universities may keep title to federally funded inventions and must prefer small firms in licensing.

  • University may keep title 35 U.S.C. 202(a)
  • Small firms first in licensing 202(c)(7)(D)
  • Program check license terms clear before a raise

Regulator support

EMA cuts fees for small firms

SMEs pay 10% of EMA’s scientific advice fee and can defer the marketing authorization fee.

  • 90% off scientific advice
  • Marketing authorization fee deferred
  • Orphan products: advice fee waived
  • Micro firms: post-authorization fees waived

The mentor pool

Mentors from the lab to the market

Mix translational scientists with people from regulatory, manufacturing, clinical operations and licensing.

  • Translational science target to candidate
  • Regulatory affairs scientific advice, filings
  • Manufacturing process and quality
  • Business development licensing and partners

Milestones to track

Track science milestones, not only rounds

Biotech value moves in steps, so ask startups to report each one.

  • Target validated data package
  • Lead candidate molecule chosen
  • Trial application IND or CTA filed
  • First patient dosed Phase 1 starts
  • Partner deal license or co-development

Mentornity AI

Ask Mentornity AI, approve what it prepares

It reads your program’s live data, answers with numbers and charts, and drafts the next step.

Answers in numbers and charts

Program health, quiet matches, waiting applications and end-of-term reports.

Matches and applications by your rules

It scores candidates with your matching rules and screens applications for you.

You set how much it does alone

Changes come as cards, or run by rule at your level.

Names stay with you

The model sees participants under aliases and never their contact details.

Answers in numbers and charts

Program health, quiet matches, waiting applications and end-of-term reports.

Matches and applications by your rules

It scores candidates with your matching rules and screens applications for you.

You set how much it does alone

Changes come as cards, or run by rule at your level.

Names stay with you

The model sees participants under aliases and never their contact details.

Claude, ChatGPT and MCP

Mentornity inside Claude and ChatGPT

Mentors and founders ask in plain words; the assistant does the work in Mentornity.

Claude, ChatGPT or any MCP app

In Claude from the connector list; ChatGPT and Cursor by server address.

Meetings, tools, forms and messages

It finds slots, plans meetings, fills in tools and forms, drafts replies.

A preview before every change

The assistant shows what will change; nothing happens until they say yes.

The program team decides

It sees only what the member sees; you can turn it off.

Claude, ChatGPT or any MCP app

In Claude from the connector list; ChatGPT and Cursor by server address.

Meetings, tools, forms and messages

It finds slots, plans meetings, fills in tools and forms, drafts replies.

A preview before every change

The assistant shows what will change; nothing happens until they say yes.

The program team decides

It sees only what the member sees; you can turn it off.

Goals and Mentornity Academy

Participants set goals, learn and earn badges

Goals in My development, guides in Mentornity Academy, and skill badges for mentors.

Their own goals in My development

They set goals and rate progress at start, mid-point, end and follow-up.

Badge courses for mentors

Seven skills, from active listening to feedback, each with a 20-question exam.

Content for mentors and founders

Research-based guides, a deck for every tool, decks for your program type.

A badge they can share

A passed exam earns a badge page they can add to LinkedIn.

Their own goals in My development

They set goals and rate progress at start, mid-point, end and follow-up.

Badge courses for mentors

Seven skills, from active listening to feedback, each with a 20-question exam.

Content for mentors and founders

Research-based guides, a deck for every tool, decks for your program type.

A badge they can share

A passed exam earns a badge page they can add to LinkedIn.

Sources

The research behind this presentation

  1. Wong, C. H., Siah, K. W. & Lo, A. W. (2019) Estimation of clinical trial success rates and related parameters Biostatistics, 20(2), 273-286
  2. DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs Journal of Health Economics, 47, 20-33
  3. United States Congress (2023) 35 U.S.C. 202, Disposition of rights (Bayh-Dole Act) United States Code, 2023 edition, Title 35, Chapter 18, U.S. Government Publishing Office
  4. European Medicines Agency (2026) Financial advantages of SME status European Medicines Agency, support for SMEs

Design for the long road

Share labs, settle IP early and plan the capital in stages.

Open your admin panel Sign in All presentations